This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
UCB, Inc.
UCB, Inc., a prominent biopharmaceutical company headquartered in the United States, has established itself as a leader in the development of innovative therapies for neurological and immunological disorders. Founded in 1928, UCB has achieved significant milestones, including the launch of groundbreaking treatments that address unmet medical needs. With a strong presence in North America and Europe, UCB focuses on core areas such as epilepsy, Parkinson's disease, and autoimmune conditions. Their unique approach combines advanced science with patient-centric solutions, setting them apart in the competitive biopharmaceutical landscape. Recognised for their commitment to research and development, UCB continues to enhance its market position through strategic partnerships and a robust pipeline of novel therapies.
DitchCarbon Score
How does UCB, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
UCB, Inc.'s score of 92 is higher than 95% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
UCB, Inc., headquartered in the US, currently does not report specific carbon emissions data for the latest year, as indicated by the absence of emissions figures. However, the company is part of a corporate family that includes UCB SA, from which it inherits climate commitments and initiatives. UCB SA has established various climate initiatives, including targets set through the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP). These commitments reflect a broader industry trend towards transparency and accountability in carbon emissions management. UCB, Inc. aligns with these initiatives, although specific reduction targets or achievements have not been disclosed. As a current subsidiary of UCB SA, UCB, Inc. is expected to adhere to the sustainability goals and climate strategies set forth by its parent company. This includes a commitment to reducing emissions across all scopes, although detailed figures and specific targets have not been provided in the available data. In summary, while UCB, Inc. does not present its own emissions data, it is linked to UCB SA's climate commitments, which are part of a growing movement within the pharmaceutical industry to address climate change and reduce carbon footprints.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 44,059,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 5,316,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 0,000 |
| Scope 3 | 568,003,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
UCB, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
